About | Rodon Biologics
Rodon Biologics, a leading biotech CRO/CDMO, has 20 years delivering protein solutions tailored for discovery research and beyond. The company specializes in engineering, producing, analyzing, and characterizing recombinant proteins, as well as small molecules derived from engineered microorganisms.
Rodon delivers comprehensive solutions—including processes, data, and products—tailored for discovery, early-stage research, preclinical development, and manufacturing. Established in 1999 as Biotecnol, the company initially focused on supporting the development of recombinant protein therapeutics and has since expanded its expertise and service offerings, specializing in cell-culture based development and production of proteins and other molecule types using engineered E.coli, Yeast, and Mammalian cells.
Our mission is to empower innovation in biotechnology and life sciences by providing exceptional solutions for protein and small molecule production. We are dedicated to accelerating discovery, development, and manufacturing processes through our expertise, advanced technologies, and collaborative partnerships.
We strive to deliver high-quality, reliable, and scalable services that enable our clients to bring transformative therapies and scientific breakthroughs to life, ultimately improving global health and well-being.
Where We Fit in the Biotech Landscape
Throughout the years, Rodon Biologics has collaborated with a diverse range of clients, from small start-ups to large pharmaceutical and biotech companies on a global scale. We have extensive experience in utilizing different expression systems for the production and purification of recombinant proteins. We support projects from the early stages of research and discovery to development and manufacturing for clinical trials. Our services encompass everything from DNA to drug product, allowing us to engineer, produce, and characterize products from a few milligrams to tens of grams for initial research. We further support ongoing development with stable cell line generation and a robust, scalable process, working in partnership with CMOs for GMP manufacturing during clinical trials.
Our experience and track record make us the right partner to support the development of your biotech products. Rodon’s approach is customer centric establishing a close and flexible working relationship contributing positively to the success of our customer’s projects as we believe their success is our success.
Expertise
Our expertise is centered around the development and production of recombinant proteins and small molecules derived from living organisms, which include:
- Monoclonal antibodies
- Multispecific antibodies or antibody fragments
- Cytokines and growth factors
- Vaccine antigens
- Protein fusion formats
- Proteins for non-therapeutic applications
- Enzymes
- Natural polymers
- Small molecules produced from engineered bacteria and/or yeast
- Novel formats
We possess a profound knowledge of protein biology and technology, supported by a proven track record of delivering high-quality protein products. Our team is highly experienced in cell line development, process development, and protein production, emphasizing the delivery of dependable solutions that foster innovation.
History | Rodon Biologics
Rodon Biologics traces its origins back to 1999, when it began operations as Biotecnol, with the aim of developing recombinant protein therapeutics such as human growth hormone, interferon, and interleukins—products now widely recognized as biosimilars. In 2013, Rodon Biologics was established as a dedicated service provider, while Biotecnol shifted its focus to developing multispecific antibody technologies and immuno-oncology products.
In 2018, Rodon was acquired by Iberfar, a Portuguese pharmaceutical CMO, becoming independent from Biotecnol. This marked the beginning of a new phase as a specialized biologics service provider. In 2023, Rodon Biologics was acquired by Chrysea, a biotechnology company specializing in healthcare and wellness products, to strengthen its synthetic biology capabilities and integrate a broader range of skills and expertise into its portfolio.
Timeline of key milestones
-
1997 - Launch of Biotecnol
Biotecnol set up its first laboratories at the Technical University of Lisbon to develop recombinant protein therapeutics, including biosimilars such as human growth hormone, interferons, and interleukins
-
1999 - First Lab Facilities
Biotecnol set up its first laboratories at the Technical University of Lisbon to develop recombiant protein therapeutics, including biosimilars such as human growth hormone, interferons, and interleukins
-
2002 - Start Service Provider Business
Biotecnol began offering its expertise in product and process development to third parties, laying the foundation for its CRO/CDMO services
-
2006 - Facility and Capability Expansion
Biotecnol secured investment to expand its facilities and technologies. Operations were relocated and new capabilities were added, including process development in yeast and mammalian cell systems
-
2011 - Tribodytm™ Development
Biotecnol ventured into product development with a hybrid business model, focusing on Tribody, an innovative tri-specific antibody format design for cancer therapy.
-
2013 - Launch Rodon Biologics
Rodon Biologics was established to manage Biotecnol's third-party services. During this period, Rodon played a key role in delivering a comprehensive CMC package for Biotecnol's Tribody, including production cell lines, processes, and bioassays
-
2018 - Acquisition by Iberfar
Rodon Biologics was acquired by Iberfar, a Portuguese pharmaceutical company, to focus exclusively on biologics services. Operations were relocated to Iberfar's campus in Barcarena, Lisbon, and promotional activities were relaunched
-
2023 - Acquired by Chrysea
This acquisition expanded Chrysea's capabilities in protein engineering, cell line development, precision fermentation, downstream processing, formulation, analytics, and biologics production
Partnerships
Rodon Biologics has a rich history of partnerships and collaborations with leading biopharmaceutical companies. In 2023, we were acquired by Chrysea Limited, a biotechnology company revolutionizing the healthcare and wellness industry with precision healthy-lifespan interventions. This acquisition has enabled us to integrate our skills and know-how in protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics, and production with Chrysea’s advanced synthetic biology capabilities. Our partnerships and collaborations have enabled us to expand our capabilities and offer a broader range of services to our clients.
Our Team
Our team at Rodon Biologics is comprised of experienced professionals with proven skills in protein research and development. Our workforce has a deep understanding of protein biology and technology, with expertise in cell line development, process development, protein production, and development optimization and characterisation. Our leadership team is committed to delivering high-quality results and exceeding client expectations, with a focus on customer-centricity and innovation. We are proud to have a team that is passionate about their work and dedicated to making a positive impact in the biopharmaceutical industry.
Follow Philip Cunnah on linkedin 